Cargando…
Determination of the optimal sample size for a clinical trial accounting for the population size
The problem of choosing a sample size for a clinical trial is a very common one. In some settings, such as rare diseases or other small populations, the large sample sizes usually associated with the standard frequentist approach may be infeasible, suggesting that the sample size chosen should refle...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516263/ https://www.ncbi.nlm.nih.gov/pubmed/27184938 http://dx.doi.org/10.1002/bimj.201500228 |
_version_ | 1783251133675864064 |
---|---|
author | Stallard, Nigel Miller, Frank Day, Simon Hee, Siew Wan Madan, Jason Zohar, Sarah Posch, Martin |
author_facet | Stallard, Nigel Miller, Frank Day, Simon Hee, Siew Wan Madan, Jason Zohar, Sarah Posch, Martin |
author_sort | Stallard, Nigel |
collection | PubMed |
description | The problem of choosing a sample size for a clinical trial is a very common one. In some settings, such as rare diseases or other small populations, the large sample sizes usually associated with the standard frequentist approach may be infeasible, suggesting that the sample size chosen should reflect the size of the population under consideration. Incorporation of the population size is possible in a decision‐theoretic approach either explicitly by assuming that the population size is fixed and known, or implicitly through geometric discounting of the gain from future patients reflecting the expected population size. This paper develops such approaches. Building on previous work, an asymptotic expression is derived for the sample size for single and two‐arm clinical trials in the general case of a clinical trial with a primary endpoint with a distribution of one parameter exponential family form that optimizes a utility function that quantifies the cost and gain per patient as a continuous function of this parameter. It is shown that as the size of the population, N, or expected size, [Formula: see text] in the case of geometric discounting, becomes large, the optimal trial size is [Formula: see text] or [Formula: see text]. The sample size obtained from the asymptotic expression is also compared with the exact optimal sample size in examples with responses with Bernoulli and Poisson distributions, showing that the asymptotic approximations can also be reasonable in relatively small sample sizes. |
format | Online Article Text |
id | pubmed-5516263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55162632017-08-02 Determination of the optimal sample size for a clinical trial accounting for the population size Stallard, Nigel Miller, Frank Day, Simon Hee, Siew Wan Madan, Jason Zohar, Sarah Posch, Martin Biom J Special Topic: ISCB2015 The problem of choosing a sample size for a clinical trial is a very common one. In some settings, such as rare diseases or other small populations, the large sample sizes usually associated with the standard frequentist approach may be infeasible, suggesting that the sample size chosen should reflect the size of the population under consideration. Incorporation of the population size is possible in a decision‐theoretic approach either explicitly by assuming that the population size is fixed and known, or implicitly through geometric discounting of the gain from future patients reflecting the expected population size. This paper develops such approaches. Building on previous work, an asymptotic expression is derived for the sample size for single and two‐arm clinical trials in the general case of a clinical trial with a primary endpoint with a distribution of one parameter exponential family form that optimizes a utility function that quantifies the cost and gain per patient as a continuous function of this parameter. It is shown that as the size of the population, N, or expected size, [Formula: see text] in the case of geometric discounting, becomes large, the optimal trial size is [Formula: see text] or [Formula: see text]. The sample size obtained from the asymptotic expression is also compared with the exact optimal sample size in examples with responses with Bernoulli and Poisson distributions, showing that the asymptotic approximations can also be reasonable in relatively small sample sizes. John Wiley and Sons Inc. 2016-05-17 2017-07 /pmc/articles/PMC5516263/ /pubmed/27184938 http://dx.doi.org/10.1002/bimj.201500228 Text en © 2016 The Author. Biometrical Journal published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Special Topic: ISCB2015 Stallard, Nigel Miller, Frank Day, Simon Hee, Siew Wan Madan, Jason Zohar, Sarah Posch, Martin Determination of the optimal sample size for a clinical trial accounting for the population size |
title | Determination of the optimal sample size for a clinical trial accounting for the population size |
title_full | Determination of the optimal sample size for a clinical trial accounting for the population size |
title_fullStr | Determination of the optimal sample size for a clinical trial accounting for the population size |
title_full_unstemmed | Determination of the optimal sample size for a clinical trial accounting for the population size |
title_short | Determination of the optimal sample size for a clinical trial accounting for the population size |
title_sort | determination of the optimal sample size for a clinical trial accounting for the population size |
topic | Special Topic: ISCB2015 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516263/ https://www.ncbi.nlm.nih.gov/pubmed/27184938 http://dx.doi.org/10.1002/bimj.201500228 |
work_keys_str_mv | AT stallardnigel determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize AT millerfrank determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize AT daysimon determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize AT heesiewwan determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize AT madanjason determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize AT zoharsarah determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize AT poschmartin determinationoftheoptimalsamplesizeforaclinicaltrialaccountingforthepopulationsize |